Transcode Therapeutics Inc (RNAZ) Stock Price, Quote & News

Company Profile

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastom...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 837 3099

Website: www.transcodetherapeutics.com

Address:

6 Liberty Square, Suite 2382, Boston, United States

ValuePrince Sep. 13 at 6:44 AM

$RNAZ 🐱

0 · Reply

Hovius Sep. 11 at 3:58 PM

$RNAZ have they regained compliance with Nasdaq or has ole Fitz fallen asleep at the wheel? 11:54 AM

2 · Reply

Trissy08 Sep. 11 at 2:16 PM

$RNAZ nearly 60% down this past month. Surely this can’t go under $1 again and another r/s? Or can it lol. Bloody thing

4 · Reply

Vedran1 Sep. 11 at 1:38 PM

$RNAZ https://ir.transcodetherapeutics.com/2026-09-10-TransCode-Therapeutics-Announces-Leadership-Transition

2 · Reply

phantomtrader75 Sep. 11 at 12:29 PM

$RNAZ Tom Fitzgerald put out to pasture.

1 · Reply

Hovius Sep. 9 at 2:35 PM

$RNAZ lol… why does this have a bullish rating? 🤣

1 · Reply

Vedran1 Sep. 8 at 7:59 PM

$RNAZ I see my order sitting for several days under the lowest trading price for the day when I placed it got filled today at 1.93.

1 · Reply

mbr60 Sep. 8 at 7:47 PM

$RNAZ soon 0.90 ❤️❤️❤️🔥

1 · Reply

Hovius Sep. 6 at 2:44 AM

$RNAZ “Bruce Campbell details five-year cancer prognosis” If anyone at RNAZ had a functional brain cell, they would contact Bruce and offer him treatment.

1 · Reply

Vedran1 Sep. 3 at 4:55 PM

$RNAZ https://clinicaltrials.gov/study/NCT05868226

1 · Reply

Transcode Therapeutics CFO Fitzgerald retiring, Tattory named interim CFO

Sep 10, 2026, 4:10 PM EDT - 2 days ago

TransCode Therapeutics Announces Leadership Transition

2026-08-31T12:15:16.000Z - 12 days ago

Transcode Therapeutics announces publication of article on TTX-MC138

Aug 31, 2026, 8:05 AM EDT - 12 days ago

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

TransCode Therapeutics Quarterly report: Q2 2026

Jul 20, 2026, 9:30 AM EDT - 7 weeks ago

TransCode Therapeutics Transcript: AGM 2026

Jul 17, 2026, 8:00 AM EDT - 1 month ago

TransCode Therapeutics Proxy statement: Proxy filing

Jul 2, 2026, 9:30 AM EDT - 2 months ago

TransCode Therapeutics Transcript: AGM 2026

Jun 30, 2026, 7:00 AM EDT - 2 months ago

TransCode Therapeutics Slides: Investor presentation

Jun 18, 2026, 7:00 AM EDT - 2 months ago

TransCode Therapeutics Slides: Investor presentation

Jun 8, 2026, 8:04 AM EDT - 3 months ago

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

2026-06-03T13:30:36.000Z - 3 months ago

Transcode reports results from Phase 1a dose escalation trial with TTX-MC138

Jun 3, 2026, 8:04 AM EDT - 3 months ago

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

Jun 2, 2026, 8:00 AM EDT - 3 months ago

TransCode Therapeutics Proxy statement: Proxy filing

2026-05-27T14:31:06.000Z - 3 months ago

Transcode Therapeutics initiates Phase 2a clinical trial with TTX-MC138

May 27, 2026, 8:04 AM EDT - 3 months ago

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 26, 2026, 8:00 AM EDT - 3 months ago

TransCode Therapeutics Proxy statement: Proxy filing

May 15, 2026, 7:00 AM EDT - 4 months ago

TransCode Therapeutics Quarterly report: Q1 2026

May 8, 2026, 8:00 AM EDT - 4 months ago

TransCode Therapeutics Proxy statement: Proxy filing

2026-05-01T15:02:13.000Z - 4 months ago

Transcode Therapeutics files to sell 1.53M shares of common stock for holders

May 1, 2026, 8:00 AM EDT - 4 months ago

TransCode Therapeutics Registration statement: Registration filing

2026-04-30T21:30:52.000Z - 4 months ago

Transcode Therapeutics files to sell 15.96M shares of common stock for holders

Apr 30, 2026, 8:00 AM EDT - 4 months ago

TransCode Therapeutics Registration statement: Registration filing

2026-04-27T12:19:47.000Z - 4 months ago

Transcode Therapeutics appoints Anna Moore as Chair of Scientific Advisory

2026-04-27T12:17:28.000Z - 4 months ago

Transcode Therapeutics signs research agreement with Michigan State University

Apr 27, 2026, 8:02 AM EDT - 4 months ago

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

Apr 15, 2026, 7:00 AM EDT - 5 months ago

TransCode Therapeutics Annual report: Q4 2025

2026-04-07T14:29:24.000Z - 5 months ago

Transcode Therapeutics signs flexible financing agreement for up to $20M

Apr 7, 2026, 8:30 AM EDT - 5 months ago

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

Apr 7, 2026, 8:00 AM EDT - 5 months ago

TransCode Therapeutics Proxy statement: Proxy filing

2026-03-03T13:13:28.000Z - 6 months ago

Transcode Therapeutics enters exclusive license agreement with Unleash

Mar 3, 2026, 8:01 AM EST - 6 months ago

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Mar 3, 2026, 7:00 AM EST - 6 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

Feb 23, 2026, 8:01 AM EST - 6 months ago

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

2026-02-05T13:12:16.000Z - 7 months ago

Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138

Feb 5, 2026, 8:04 AM EST - 7 months ago

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

2026-01-06T13:05:32.000Z - 8 months ago

Transcode Therapeutics announces publication of data supporting TTX-MC138

Jan 6, 2026, 8:01 AM EST - 8 months ago

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Dec 23, 2025, 7:00 AM EST - 8 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

Dec 22, 2025, 8:01 AM EST - 8 months ago

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dec 12, 2025, 7:00 AM EST - 9 months ago

TransCode Therapeutics Registration statement: Registration Filing

2025-12-11T13:15:55.000Z - 9 months ago

Transcode, Quantum Leap announce new collaboration to study TTX-MC138

Dec 11, 2025, 8:05 AM EST - 9 months ago

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

Nov 17, 2025, 8:01 AM EST - 9 months ago

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Nov 14, 2025, 4:00 PM EST - 10 months ago

TransCode Therapeutics Quarterly report: Q3 2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 11 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

2025-10-14T12:15:50.000Z - 11 months ago

Transcode Therapeutics’ TTX-MC138 achieves safety endpoint in Phase 1a study

Oct 14, 2025, 8:06 AM EDT - 11 months ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

2025-10-08T13:45:31.000Z - 11 months ago

Transcode Therapeutics Inc trading resumes

2025-10-08T13:40:35.000Z - 11 months ago

Transcode Therapeutics Inc trading halted, volatility trading pause

2025-10-08T12:16:56.000Z - 11 months ago

Transcode Therapeutics to acquire Polynoma

Oct 8, 2025, 8:00 AM EDT - 11 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 11 months ago

TransCode Therapeutics Proxy statement: Proxy Filing

Aug 29, 2025, 9:30 AM EDT - 1 year ago

TransCode Therapeutics Transcript: AGM 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Quarterly report: Q2 2025

2025-07-23T15:35:21.000Z - 1 year ago

Transcode Therapeutics Inc trading resumes

2025-07-23T15:30:19.000Z - 1 year ago

Transcode Therapeutics Inc trading halted, volatility trading pause

Jul 15, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

May 28, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

2025-05-14T23:50:13.000Z - 1 year ago

Transcode Therapeutics Inc trading halted, news pending

May 14, 2025, 4:00 PM EDT - 1 year ago

TransCode Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:05 AM EDT - 1 year ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 5, 2025, 5:07 PM EDT - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 1 year ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 9:30 AM EDT - 1 year ago

TransCode Therapeutics Transcript: AGM 2025

May 1, 2025, 9:01 AM EDT - 1 year ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Apr 21, 2025, 4:37 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Annual report: Q4 2024

Apr 16, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:37 PM EDT - 1 year ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 25, 2025, 6:24 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 23, 2025, 11:11 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 13, 2025, 7:47 AM EDT - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Feb 25, 2025, 4:15 PM EST - 1 year ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 6, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 4, 2025, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Jan 14, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 7, 2025, 8:00 AM EST - 1 year ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Dec 30, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Dec 19, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 6, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Registration statement: Registration Filing

Nov 29, 2024, 4:25 PM EST - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 27, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 14, 2024, 5:00 PM EST - 1 year ago

TransCode Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Nov 5, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Oct 28, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 5, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Jul 24, 2024, 4:05 PM EDT - 2 years ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 2 years ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 4:07 PM EDT - 2 years ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

May 29, 2024, 9:15 AM EDT - 2 years ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 20, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

May 13, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 3, 2024, 9:10 AM EDT - 2 years ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Earnings release: Q4 2023

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 11, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 6, 2024, 4:15 PM EST - 2 years ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Feb 20, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Jan 31, 2024, 4:05 PM EST - 2 years ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 29, 2024, 8:30 AM EST - 2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 22, 2024, 4:45 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 2 years ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

ValuePrince Sep. 13 at 6:44 AM

$RNAZ 🐱

0 · Reply

Hovius Sep. 11 at 3:58 PM

$RNAZ have they regained compliance with Nasdaq or has ole Fitz fallen asleep at the wheel? 11:54 AM

2 · Reply

Trissy08 Sep. 11 at 2:16 PM

$RNAZ nearly 60% down this past month. Surely this can’t go under $1 again and another r/s? Or can it lol. Bloody thing

4 · Reply

Vedran1 Sep. 11 at 1:38 PM

$RNAZ https://ir.transcodetherapeutics.com/2026-09-10-TransCode-Therapeutics-Announces-Leadership-Transition

2 · Reply

phantomtrader75 Sep. 11 at 12:29 PM

$RNAZ Tom Fitzgerald put out to pasture.

1 · Reply

Hovius Sep. 9 at 2:35 PM

$RNAZ lol… why does this have a bullish rating? 🤣

1 · Reply

Vedran1 Sep. 8 at 7:59 PM

$RNAZ I see my order sitting for several days under the lowest trading price for the day when I placed it got filled today at 1.93.

1 · Reply

mbr60 Sep. 8 at 7:47 PM

$RNAZ soon 0.90 ❤️❤️❤️🔥

1 · Reply

Hovius Sep. 6 at 2:44 AM

$RNAZ “Bruce Campbell details five-year cancer prognosis” If anyone at RNAZ had a functional brain cell, they would contact Bruce and offer him treatment.

1 · Reply

Vedran1 Sep. 3 at 4:55 PM

$RNAZ https://clinicaltrials.gov/study/NCT05868226

1 · Reply

Vedran1 Sep. 3 at 3:53 PM

$RNAZ Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer ... ... Management will discuss the Company's upcoming clinical milestones, strategic partnership opportunities, and the potential to create value across both its internal pipeline and proprietary delivery platform. With multiple programs advancing and additional Phase 2a and Phase 1a readouts expected through 2027, TransCode is entering a period with several potential clinical and strategic catalysts. ... ... To register for the free webinar, please visit: https://www.redchip.com/webinar/RNAZ/81817787778 ... ... Questions can be pre-submitted to [email protected] or online during the live event. ... --- Source: Access Newswire (Thinkorswim)

1 · Reply

Vondde Sep. 3 at 1:00 PM

$RNAZ The PRE-I-SPY ClinicalTrials.gov record was updated on September 2 to add TTX-MC138 and is listed as "Recruiting". This is strong circumstantial evidence that phase 2a enrollment should begin imminently. Source: https://trialbeacon.cn/trials/NCT05868226

0 · Reply

Hovius Sep. 2 at 7:43 PM

$RNAZ another daily dump incoming?

1 · Reply

Hovius Sep. 1 at 5:22 PM

$RNAZ beautiful early stage data.. thank you for summarizing it. kind of reminiscent of all their data for past 3-4 years… they do some great early stage studies. seems to be their specialty.. I just wish they would get done/started with these phase 2 studies… oh well, keep hope alive..

1 · Reply

Vedran1 Sep. 1 at 3:11 PM

$RNAZ The most recent "TCT" preclinical study involved implanting breast cancer cells prone to bone metastasis directly into the tibial bones of mice. I read the study and like it. It is a logical continuation of existing work, which further expands the potential applications of the MC/TTX delivery platform to deliver therapeutics (such as anti-miR-10b) targeting cancer metastasis by inhibiting miR-10b, a significant mediator promoting the seeding and homing of many types of cancer metastases. Treatment prolonged the median survival of mice with bone metastases from about 50 days to approximately 85 days.

1 · Reply

Vedran1 Aug. 31 at 8:44 PM

$RNAZ https://www.mdpi.com/2072-6694/18/17/2731 Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics -- The above is a link to the full article. Did not read it yet short of the PR and the abstract. Will read it sometime today or tomorrow. So far, It is "Just" another preclinical success - with usual "investors" reaction.

0 · Reply

athebeast Aug. 31 at 4:12 PM

$RNAZ Short city 📉📉📉

1 · Reply

phantomtrader75 Aug. 31 at 2:55 PM

$RNAZ WTFH 😡

0 · Reply

RealisticBullz Aug. 31 at 2:13 PM

$RNAZ The company maintains a live equity line and an effective shelf registration which provide immediate mechanisms to sell shares into price strength. 424B3 filing ↗

0 · Reply

Hovius Aug. 31 at 2:08 PM

$RNAZ dilution is due to Anna having to work over the weekend to write her paper.. overtime don’t come cheap..

0 · Reply

Itinerant Aug. 31 at 1:58 PM

$RNAZ Looks to me like the company is about to dilute. What do you think?

1 · Reply

mbr60 Aug. 31 at 1:40 PM

$RNAZ 🥳🥳🥳❤️

0 · Reply

Market Cap	28.61M
Revenue (ttm)	0.00
Net Income (ttm)	-34.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	11,400
Avg Vol	50,566
Day's Range	N/A - N/A
Shares Out	16.93M
Stochastic %K	9%
Beta	1.16
Analysts	Strong Buy
Price Target	$10.00